Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action

Savara Inc

RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.
Royalty rates tiered from 7.0% to 1.0% of U.S. net sales; 7.0% tier rises to 9.5% if prior-year sales fall short.
Royalty capped at $187.5M; company expects effective rate in low-single digits over life of agreement.
Securities class action filed Sept 8, 2025 alleging misstatements about MOLBREEVI regulatory filings; company intends to defend.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.